5 Stocks Pushing The Drugs Industry Downward

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 31 points (0.2%) at 15,006 as of Tuesday, July 2, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,611 issues advancing vs. 1,325 declining with 103 unchanged.

The Drugs industry currently sits up 0.4% versus the S&P 500, which is up 0.4%.

TheStreet would like to highlight 5 stocks pushing the industry lower today:

5. Achillion Pharmaceuticals ( ACHN) is one of the companies pushing the Drugs industry lower today. As of noon trading, Achillion Pharmaceuticals is down $2.05 (-24.5%) to $6.31 on heavy volume. Thus far, 8.3 million shares of Achillion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $6.30-$6.72 after having opened the day at $6.58 as compared to the previous trading day's close of $8.36.

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on the development of antivirals for the treatment of chronic hepatitis C viral (HCV) infection. Achillion Pharmaceuticals has a market cap of $789.8 million and is part of the health care sector. Shares are up 2.1% year to date as of the close of trading on Monday. Currently there are 9 analysts that rate Achillion Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Achillion Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow, deteriorating net income, poor profit margins and feeble growth in its earnings per share. Get the full Achillion Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, Illumina ( ILMN) is down $2.94 (-3.9%) to $73.33 on average volume. Thus far, 997,945 shares of Illumina exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $73.22-$76.25 after having opened the day at $75.83 as compared to the previous trading day's close of $76.27.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $9.3 billion and is part of the health care sector. The company has a P/E ratio of 99.9, above the S&P 500 P/E ratio of 17.7. Shares are up 34.6% year to date as of the close of trading on Monday. Currently there are 9 analysts that rate Illumina a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Illumina Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Vertex Pharmaceuticals ( VRTX) is down $0.57 (-0.7%) to $79.86 on light volume. Thus far, 860,033 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 2.5 million shares. The stock has ranged in price between $79.21-$81.88 after having opened the day at $80.60 as compared to the previous trading day's close of $80.43.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Vertex Pharmaceuticals has a market cap of $17.7 billion and is part of the health care sector. Shares are up 91.1% year to date as of the close of trading on Monday. Currently there are 14 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Vertex Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Biogen Idec ( BIIB) is down $0.92 (-0.4%) to $216.95 on average volume. Thus far, 621,337 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $215.22-$219.28 after having opened the day at $217.49 as compared to the previous trading day's close of $217.88.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $51.1 billion and is part of the health care sector. The company has a P/E ratio of 34.2, above the S&P 500 P/E ratio of 17.7. Shares are up 47.0% year to date as of the close of trading on Monday. Currently there are 12 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Biogen Idec Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Amgen ( AMGN) is down $1.16 (-1.2%) to $96.34 on average volume. Thus far, 2.2 million shares of Amgen exchanged hands as compared to its average daily volume of 3.8 million shares. The stock has ranged in price between $95.40-$97.28 after having opened the day at $96.79 as compared to the previous trading day's close of $97.49.

Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $74.0 billion and is part of the health care sector. The company has a P/E ratio of 16.7, below the S&P 500 P/E ratio of 17.7. Shares are up 13.1% year to date as of the close of trading on Monday. Currently there are 9 analysts that rate Amgen a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Amgen Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).
null